The lack of tumour-specific antigens and control over T-cell activity limits the development of CAR-T cell therapies for solid tumours. Here the authors present an avidity-controlled CAR platform with inducible logic control functions.
- Benjamin Salzer
- Christina M. Schueller
- Manfred Lehner
